CRISPR genome-editing trials for treating beta thalassaemia and sickle cell disease are being extended to include people aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. This New Scientist article has more information...
Related Articles
Image by Matthew Daniels via the Wellcome Collection. Depicts human cells, showing the stages of cell division.
Podcast Review: How Far Could Genome Editing Go?
The BBC's CrowdScience podcast calls on listeners to ask the scientific questions they've always wanted answered, from medicine, to the Earth and beyond. In the latest episode of the series, host Caroline Steel delves into the world of genome editing, from success stories in the clinic, to the pragmatic ethical concerns...